share_log

Evercore ISI Group Upgrades BioNTech to Outperform, Raises Price Target to $125

Evercore ISI Group Upgrades BioNTech to Outperform, Raises Price Target to $125

Evercore ISI集团将biontech升级为表现优异,并将目标股价上调至125美元
Benzinga ·  2024/11/19 04:23  · 评级/大行评级

Evercore ISI Group analyst Cory Kasimov upgrades BioNTech (NASDAQ:BNTX) from In-Line to Outperform and raises the price target from $110 to $125.

Evercore ISI Group 分析师Cory Kasimov将biontech(纳斯达克:BNTX)评级从持平上调至跑赢大盘,并将价格目标从110美元提高至125美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发